

FORM 7

MONTHLY PROGRESS REPORT

Name of CNSX Issuer: Certive Solutions Inc. (the "Company" or "Issuer").

Trading Symbol: CBP

Number of Outstanding Listed Securities: 134,214,429

Date: For the period ending March 31, 2020

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by the CNSX Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the CNSX.ca website.

This report is intended to keep investors and the market informed of the Issuer's on-going business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the CNSX Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact. Some of these monthly numbers do change as adjustments are made after month end by auditors.

Recent announcements by the Company of new clients and a Preferred Partnership agreement are a result of the Company's focus on business development and client services leveraging its deep understanding and connectivity in the healthcare industry. Once fully onboarded, these initiatives will result in revenue growth while the Company continues its efforts to control costs and improve quality.

The Issuer's estimated gross operating revenues from its Omega division are as follows:

Omega Division (in US Dollars)			
February	2019	\$	71,771
March	2019	\$	112,508
April	2019	\$	63,245
May	2019	\$	72,129
June	2019	\$	68,815
July	2019	\$	48,193
August	2019	\$	124,889
September	2019	\$	92,552
October	2019	\$	135,964
November	2019	\$	114,406
December	2019	\$	140,594
January	2020	\$	117,911
February	2020	\$	130,498
March	2020	\$	110,465

Estimated amounts are accrued as revenue for the completed work. After the hospital receives payment from the payer, an invoice is generated and sent to the hospital for the Company's contingency fee, which is generally collected approximately 90 days after the work was completed. Such estimated monthly amounts are subject to change. March 2020 revenues were affected because of the Ft. Lauderdale office move-out and the decision to work remotely during the coronavirus crisis. Servers are being securely hosted and the furnishings are in storage until new office space is leased in a few months, which will result in temporary, but significant cost savings. Based on the onboarding of the previously announced new clients, the Company anticipates increasing revenue trends going forward.

2. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.
- None.**
3. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.
- None.**
4. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.
- None.**
5. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.
- None.**
6. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.
- None.**
7. Describe the acquisition of new customers or loss of customers.
- None.**
8. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.
- No changes.**
9. Report on any employee hiring's, terminations or lay-offs with details of anticipated length of lay-offs.
- No changes.**
10. Report on any labour disputes and resolutions of those disputes if applicable.
- No changes.**

11. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

No changes.

12. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

As previously reported, the Company initiated a US\$1.2M Private Placement Offering of 12% four-year Convertible Promissory Notes, which upon the Offering's Closing will become convertible at US\$0.14/share. This Offering is secured by 1/3 of the cash collections from the recently announced new contract to serve the six-hospital system located in the Northeastern United States. Upon conversion, Certive's Common Shares issued under the Private Placement will be subject to a regulatory resale restriction for U.S. lenders/investors. These funds will be used for working capital to fund the operations and growth efforts of its Omega division as well as for Corporate working capital needs.

13. Provide details of any securities issued and options or warrants granted.

As mentioned above in item 12, the conversion option that accompanies the Private Placement Offering of 12% four-year Convertible Promissory Notes is a conversion rate of US\$0.14/share.

The Board granted 100,000 10-year stock options each to the two independent Board Members, which vest in one year. Once vested, the stock options are exercisable at CDN\$0.05.

The Board also granted 200,000 10-year incentive stock options to a new member of the Company's Advisory Council. These stock options vest if the Company's share price achieves \$0.30/share on a volume weighted basis for a 45-day period prior to January 29, 2021. Once vested, the stock options are exercisable at CDN\$0.05.

In settlement of a dispute with a vendor, the Company issued 1,000,000 shares during March as directed by the vendor pursuant to a settlement agreement reached in September of 2018.

14. Provide details of any loans to or by Related Persons.

With Board approval, certain related parties continue to provide working capital to the Company loaning funds to the Issuer via the 12% four-year Convertible Promissory Notes described above in items 12 & 13, 12% short-term demand notes and non-interest-bearing advances.

15. Provide details of any changes in directors, officers or committee members.
None. On March 11, 2020, the Company's Annual General Meeting of the Shareholders was held in Vancouver, CA, and as a result, there were no changes in directors, officer or committee members.
16. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.
None.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CNSX that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: April 6, 2020

Tim Hyland, CFO

Name of Director or Senior Officer

"Tim Hyland"

Signature

Chief Financial Officer

Official Capacity

Issuer Details Name of Issuer Certive Solutions Inc.	For Month Ending March 31, 2020	Date of Report YY/MM/DD 20/04/06
Issuer Address 7373 E. Doubletree Ranch Road, Suite 210		
City/Province/Postal Code Scottsdale Arizona 85258	Issuer Fax No. (480) 922-5327	Issuer Telephone No. (480) 922-5327
Contact Name Tim Hyland	Contact Position CFO	Contact Telephone No. (480) 922-5327
Contact Email Address thyland@certive.com	Web Site Address www.certivehealth.com	